Another Benefit of Gout Treatment: CV Risk Reduction
Growing evidence suggests that a guideline-directed, treat-to-target strategy in patients with gout not only controls the disease but also reduces cardiovascular risks.
Source: medscape.com
Inflammatory Conditions News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Inflammatory Conditions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Inflammatory Conditions Today - Breaking & Trending Today
In RA Treatment, Don't Overlook Underlying CV Risks
Disease-modifying antirheumatic drugs can reduce some cardiovascular risk in patients with rheumatoid arthritis, but questions remain if that's enough when statin use lags.
Source: medscape.com
Evidence Builds to Support Colchicine in Treating ASCVD
Colchicine, a legacy drug that received a new indication in 2023 for cardiovascular disease, can treat arterial inflammation after a heart attack, a principal investigator of clinical trials said.
Source: medscape.com
What Is Amyloidosis?
Amyloidosis is a rare condition that develops when your body produces too many amyloid proteins, which can damage your organs and tissues.
Source: yahoo.com
GSK completes acquisition of Aiolos Bio for up to $1.4 billion
GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions. GSK will pay $1 billion upfront and up to $400 million in success-based milestone payments. "In addition, GSK will also be responsible for success-based milestone payments as well as tiered royalties owed to Jiangsu Hengrui Pharmaceuticals Co, Ltd," the group said.
Source: yahoo.com